FoRx Therapeutics
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Lichtstrasse 35, Basel, Basel-City, 4056...Website
www.forxtherapeutics.comRevenue
$9.3 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About FoRx Therapeutics
FoRx Therapeutics is a privately held clinical-stage biotechnology company pioneering precision therapeutics targeting the DNA Damage Response in treatment-resistant cancers. Its lead product candidate FORX-428, an oral small molecule PARG inhibitor, is in Phase 1 testing to treat advanced solid tumors.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is FoRx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if FoRx Therapeutics is spiking on competitors!
Product Launch: Get notified when FoRx Therapeutics launches new products
FoRx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if FoRx Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once FoRx Therapeutics has new funding data
Earning: See what the market has to say on FoRx Therapeutics recently announced quarterly report
Check if FoRx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at FoRx Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined FoRx Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
FoRx Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
FoRx Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about FoRx Therapeutics.
FoRx Therapeutics financials insights
Gather financial insights about FoRx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Seed
$10.8M
2025
Series A
$50M
FoRx Therapeutics Tech Stack
A closer look at the technologies used by FoRx Therapeutics
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
FoRx Therapeutics News & Media
FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor
FoRx Therapeutics closes an insider-led USD 50 million (CHF 40 million) Series A financing.FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
Basel, Switzerland – August 11, 2025 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the dosing of the first patient in a first-in-human clinical study of FORX-428, a novel PARG inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors.FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate
BASEL, Switzerland--(BUSINESS WIRE)-- #PARG--FoRx Therapeutics appoints Dr. Jens Wurthner, PhD, as Chief Medical Officer and reports progress toward IND submission by mid-2025 for FORX-428
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding FoRx Therapeutics
Sign Up For FreeTo access detailed company insights
FoRx Therapeutics is a privately held clinical-stage biotechnology company pioneering precision therapeutics targeting the DNA Damage Response in treatment-resistant cancers. Its lead product candidate FORX-428, an oral small molecule PARG inhibitor, is in Phase 1 testing to treat advanced solid tumors.... Read More
